Carlos Rodriguez

Carlos Rodriguez

Auto-generated profile, based on publicly available information

Carlos Rodriguez

Biochemistry University of California Riverside CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DNDong Hyun Nam
Dong Hyun Nam
CRCarlos Rodriguez
Carlos Rodriguez
ARAlbert G. Remacle
Albert G. Remacle
ASAlex Y. Strongin
Alex Y. Strongin
XGXin Ge
Xin Ge
Proteases are frequent pharmacological targets, and their inhibitors are valuable drugs in multiple pathologies. The catalytic mechanism and the active-site fold, however, are largely conserved among the protease classes, making the development of the selective inhibitors exceedingly challenging. In our departure from the conventional strategies, we reviewed the structure of known camelid inhibitory antibodies, which block enzyme activities via their unusually long, convex-shaped paratopes. We synthesized the human Fab antibody library (over 1.25 × 109 individual variants) that carried the extended, 23- to 27-residue, complementarity-determining region (CDR)–H3 segments. As a proof of principle, we used the catalytic domain of matrix metalloproteinase-14 (MMP-14), a promalignant protease and a drug target in cancer, as bait. In our screens, we identified 20 binders, of which 14 performed as potent and selective inhibitors of MMP-14 rather than as broad-specificity antagonists. Specifically, Fab 3A2 bound to MMP-14 in the vicinity of the active pocket with a high 4.8 nM affinity and was similarly efficient (9.7 nM) in inhibiting the protease cleavage activity. We suggest that the convex paratope antibody libraries described here could be readily generalized to facilitate the design of the antibody inhibitors to many additional enzymes.

15 December 2016 in Protein Engineering, Design and Selection
Verified
Journal Article
Open access
PDF file
DNDong Hyun Nam
Dong Hyun Nam
KFKuili Fang
Kuili Fang
CRCarlos Rodriguez
Carlos Rodriguez
TLTyler Lopez
Tyler Lopez
XGXin Ge
Xin Ge
Matrix metalloproteinase-14 (MMP-14) plays important roles in cancer metastasis, and the failures of broad-spectrum MMP compound inhibitors in clinical trials suggested selectivity is critical. By grafting an MMP-14 specific inhibition motif into complementarity determining region (CDR)-H3 of antibody scaffolds and optimizing other CDRs and the sequences that flank CDR-H3, we isolated a Fab 1F8 showing a binding affinity of 8.3 nM with >1000-fold enhancement on inhibition potency compared to the peptide inhibitor. Yeast surface display and fluorescence-activated cell sorting results indicated that 1F8 was highly selective to MMP-14 and competed with TIMP-2 on binding to the catalytic domain of MMP-14. Converting a low-affinity peptide inhibitor into a high potency antibody, the described methods can be used to develop other inhibitory antibodies of therapeutic significance.

13 May 2022 in The FASEB Journal
Verified
Journal Article
Closed access
GBGregor Blaha
Gregor Blaha
SDStephen Diggs
Stephen Diggs
TTTimothy K. Tam
Timothy K. Tam
SHSheron Hakopian
Sheron Hakopian
CRCarlos Rodriguez
Carlos Rodriguez